LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Handheld Coagulation Analyzer Recieves FDA Clearance

By LabMedica International staff writers
Posted on 18 Oct 2016
Print article
Image: The Xprecia Stride coagulation analyzer brings hemostasis testing accuracy and quality from lab to simple point-of-care. Color-coded caps can be used to designate users or locations (Photo courtesy of Siemens Healthineers).
Image: The Xprecia Stride coagulation analyzer brings hemostasis testing accuracy and quality from lab to simple point-of-care. Color-coded caps can be used to designate users or locations (Photo courtesy of Siemens Healthineers).
For the first time, the US Food & Drug Administration (FDA) has given 510(k) clearance for a point-of-care (POC) Prothrombin Time / International Normalized Ratio (PT/INR) device based on the new rules published in March 2016. Winner of multiple design awards (e.g. Red Dot Award and iFDesign Award), the device includes a number of innovations and features not found on most other POC analyzers.

The handheld portable Xprecia Stride coagulation analyzer, from Siemens Healthineers (or Siemens Healthcare; Erlangen, Germany), delivers fast, reliable PT/INR testing for POC monitoring and management of oral anticoagulation therapy with the vitamin K antagonist warfarin. Results are available within minutes. Features promote safety, accuracy, and ease of use.

“Among the many challenges of POC testing, accuracy and safety have become paramount to both the user and patient. With the Xprecia Stride analyzer, Siemens Healthineers delivers on the promise to bring a safe and lab-accurate test directly to the patient,” said Michael Sampson, senior vice president, Point of Care, Siemens Healthineers, North America, “The Xprecia Stride analyzer is designed to be safe, efficient, and ergonomically friendly. By adding the Xprecia Stride analyzer to our existing product portfolio in the US, we now have the ability to cover the full range of hemostasis testing from the hospital lab to the physician’s office.”

Millions of PT/INR tests are administered worldwide each year as part of therapy monitoring for patients with a host of conditions, including atrial fibrillation, heart valve replacement surgery, deep vein thrombosis, and congenital heart defects, among others. Xprecia Stride was designed to meet the growing demand for PT/INR results in physician offices and walk-in clinics to help healthcare professionals make informed decisions about patient care.

No bigger than a smartphone and weighing just 10.5 oz, Xprecia Stride can be held at virtually any angle and brought directly to the patient’s finger for efficient and comfortable blood sample application. Only a small sample volume is required, obtained by fresh capillary (fingerstick) draw of whole blood. Results are expressed as INR.

Xprecia Stride utilizes the same Dade Innovin reagent used by Siemens Healthineers central lab analyzers to minimize potential for variability. Studies have shown the performance to be equivalent to a reference laboratory hemostasis system (White Paper available online).

To further address challenges, the Xprecia Stride analyzer was designed to provide intuitive user interface and features such as an integrated barcode scanner (enters lot calibration information and operator and patient IDs) to simplify data capture and improve patient workflow. Data such as patient and QC results can be transferred via USB port. Xprecia Stride uses simple icons and animation in a color display more commonly found in mobile devices than medical instruments.

Safety features include a first-of-its kind test strip eject button that allows the user to eject and easily dispose of a used test strip without touching it, minimizing potential biohazard exposure.

Taken together, these innovations enable better care for the growing number of patients receiving anticoagulation therapy.

Related Links:
Siemens Healthineers


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.